Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.12%
#3 Glidr Glidr +36.87%
#4 CoW Protocol CoW Protocol +35.00%
#5 RedStone RedStone +28.08%
#6 Humanity Humanity +25.92%
#7 Codatta Codatta +22.12%
#8 Walrus Walrus +20.05%
#9 Enso Enso +18.97%
#10 Tutorial Tutorial +17.31%
Coin of the day
EXOD EXOD
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc.

JUNS
Classement en actions #36527
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in... Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
Prix de l'action
$5.34
Dernière synchronisation: 2026-08-14
Capitalisation boursière
$2.59M
Changement (1 jour)
-11.00%
Changement (1 an)
313.95%
Pays
US
Échange Jupiter Neurosciences, Inc. (JUNS)

Catégorie

Healthcare
Ratio P/B pour Jupiter Neurosciences, Inc. (JUNS)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Jupiter Neurosciences, Inc., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Jupiter Neurosciences, Inc. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE